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Background. New-onset diabetes after transplantation (NODAT) is associatedwith decreased graft survival and an increased risk for
cardiovascular disease. The objective of this study was to evaluate the risk factors for development of NODAT and its’ relationship
with arterial stiffness and left ventricular mass index (LVMI) in kidney transplant recipients. Methods. 159 kidney transplant
recipients were selected fromour transplantation center who underwent renal transplantation between years 2007 and 2010.Results.
Among 159 patients, 57 (32.2%) patients were with NODATwho were significantly older than patients without diabetes (𝑃: 0.0001).
Patients with NODAT had significantly higher pulse wave velocity (PWv) (𝑃: 0.033) and left ventricular mass index LVMI (𝑃: 0.001)
compared to patients without NODAT. Further analysis was done according to LVMI as follows: LVMI > 130 g/m2 (𝑛: 57) and LVMI
≤ 130 g/m2 (𝑛: 102). We observed higher office systolic and diastolic BP, serum trygliceride, glucose, creatinine, age, and HbA1c (𝑃:
0.0001) levels in patients with LVMI > 130 g/m2. Linear regression analysis revealed that HbA1c was themajor determinant of LVMI
(𝑃: 0.026, 𝛽: 0.361). Conclusions. HbA1c is the major determinant of LVMI, so strict control of serum glucose levels is essential for
preventing cardiovascular disease in patients with NODAT.
1. Introduction
New-onset diabetes after transplantation (NODAT) is
a serious complication associated with decreased graft and
patient survival as well as an increased risk for cardiovascular
disease [1, 2]. New-onset diabetes after transplantation most
frequently develops in the early posttransplant period,
usually within the first year [2], and has additionally been
linked with all-cause mortality, increased susceptibility to
infections, acute rejection, chronic graft dysfunction, and
decreased quality of life [3–6].
The precise incidence of NODAT is difficult to deter-
mine, with a widely dispersed reported incidence between
2% and 50% [7], due to the lack of a uniform definition,
varying immunosuppressive regimens, and variable duration
of follow-up [1, 8].Multiple risk factors forNODAThave been
identified, including advanced age at transplantation, ethnic-
ity, and obesity, a family history of diabetes, impaired glucose
tolerance before transplantation, CMV infection, and drugs
[9]. The evaluation of all these factors and determination of
the treatment modalities will be a guide in the prevention of
NODAT complications.
Presence of left ventricular hypertrophy and arterial stiff-
ness are independent determinants of cardiovascular disease
in patients with end-stage renal disease [10]. Left ventricular
hypertrophy might have negative impact on development of
myocardial ischemia, arrhythmias, congestive heart failure,
and sudden death [11, 12]. Renal transplantation generally
leads to regression of left ventricular hypertrophy though
it may persist or develop de novo in some patients [12]. In
previous literature, a higher proportion of prediabetic states
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and NODAT were shown to be related with increasing left
ventricular mass after transplantation [11, 13, 14].
Arterial stiffness is an independent predictor of car-
diovascular events in patients with hypertension [15–17],
ESRD, and diabetes mellitus [18]. Pulse wave velocity is an
easy (PWv), noninvasive, and repeatable tool that could be
used to evaluate the degree of atherosclerosis and arterial
stiffness [19]. A number of studies revealed that restoration
of renal function after renal transplantation could partially
improve increased arterial stiffness [20, 21]. On the other
hand, it has also been shown that renal transplant recipients
with glucose intolerance had increased PWv, suggesting that
glucose intolerance may induce atherosclerosis [4, 5, 22].
The objective of this study was to evaluate the risk factors
for the development of NODAT and its relationship with
arterial stiffness and left ventricular hypertrophy in kidney
transplant recipients.
2. Methods
2.1. Selection of the Population. Between years 2007 and
2010, 63 (23.59%) kidney transplant patients out of 267 were
diagnosed to have NODAT in our center. Among these,
159 kidney transplant recipients were selected according to
the following exclusion criteria: (1) irregular drug usage or
patient incompliance, (2) lack of regular follow-up data,
(3) pretransplant diabetes mellitus history, (4) bone marrow
transplant or other solid organs before or at the time of
transplantation (including previous kidney transplantation),
(5) malign disease, rheumatologic or chronic inflammatory
disease of unknown origin, systemic vasculitis history, (6)
acute rejection periods after the first year of transplantation,
(7) unstable cardiac disease including heart failure (ejec-
tion fraction < 50%) and/or ischemic heart disease history
(myocardial infarction, need for cardiac revascularization),
(8) atrial fibrillation or elevated heart rate (>100 beats/min),
(9) coronary bypass before or after transplantation, (10)
transiently elevated fasting plasma glucose (FPG) or dia-
betic blood glucose profile during the first 3 posttransplant
months, (11) graft failure (glomerular filtration (GFR) rate
< 30mL/min), and (12) history of peritoneal dialysis before
transplantation.
New-onset diabetes after transplantation was defined as a
fasting plasma glucose (FPG) level ≥ 126mg/dL (7mmol/L)
or symptoms of diabetes plus casual plasma glucose con-
centrations ≥200mg/dL (11.1mmol/L), confirmed by repeat
testing on a different day [23]. According to these criteria, 63
patients were diagnosed as NODAT between years 2007 and
2010 but after the exclusion criteria of our study 57 patients
with and 102 patients without NODAT were included in the
study.
2.2. Clinical and Biochemical Measurements. All patients’
data were recorded from clinical charts. Visits in outpatient
clinic were organized as follows: three visits per week during
the first 2 weeks; two visits per week until Day 60; weekly
visits until Day 120; monthly visits during the first year; one
visit every other month during the second year; and four
visits per year thereafter until death or end-stage renal disease
(i.e., dialysis or retransplantation). The following parameters
were collected: (1) age, (2) gender, (3) posttransplantation
duration, (4) pretransplant hemodialysis duration, (5) acute
rejection episodes, (6) use of statins, ace inhibitor (ACE) or
angiotensin receptor blocker (ARB), (7) immunosuppressive
treatment (mycophenolate, cyclosporine, tacrolimus, and
sirolimus use), (8) pretransplant lipid profile (values in
the last month before transplantation), (9) posttransplant
lipid profile (mean value), (10) FPG and HbA1c levels
(mean value), (11) office blood pressure measurements, (12)
hemoglobin, calcium, phosphorus, albumin and parathyroid
hormone levels, (13) creatinine and eGFR (MDRD equation),
and (14) cytomegalovirus infection history.
Mean values were arithmetic means of each parameter
that were collected from patient charts at monthly basis after
the first posttransplant of 6 months while other parameters
were collected as single values at study inclusion.
Maintenance immunosuppressive treatment included
prednisone with a gradual tapering and mycophenolate
mofetil or sodium associated with cyclosporine, tacrolimus,
or sirolimus in most patients. Target through levels at
3 months were 150–250 ng/mL for cyclosporine and 8–
12 ng/mL for tacrolimus and sirolimus. Steroids were tapered:
500mg methylprednisolone intravenous (iv) on Day 0,
250mg iv on Day 1, and 100mg iv on Day 2 and 50mg
prednisolone perorally (po) from Day 3 to Day 6, 0.5mg/kg
BW po from Day 7 with a reduction by 5mg every 2
weeks until 15mg/day, and then 2.5mg every 2 weeks until
a maintenance dose 5mg was achieved. All patients were
under 5mg prednisolone treatment within the maintenance
immunosuppressive regimen 6 months after transplantation.
Antidiabetic treatment modalities (diet and lifestyle changes,
oral antidiabetic drugs, or insulin) were also recorded for
patients with NODAT.
Body compositions of all patients were analyzed by using
the body composition analyzer (Tanita BC-420MA). Fat
mass, fat free mass, muscle mass, visceral fat mass, and body
mass index were calculated for each patient.
All patients underwent echocardiographic examinations
(Siemens Acuson C256, Mountain View, CA, 2000 with 3V2c
transducer probe) by the same operator and left ventricular
mass was calculated according to the Devereux formula and
indexed to body surface area to give left ventricular mass
index (LVMI) (g/m2). Left ventricular mass index values
greater than 130 g/m2 (𝑛: 57) were defined as high left
ventricular mass.
Pulse wave velocity (PWv) is defined as the velocity of
the arterial pulse for moving along the vessel wall. Pulse
wave velocity along the aorta was measured by using two
ultrasound or pressure sensitive transducers fixed transcu-
taneously over the course of a pair of arteries separated by
a known distance: the femoral and right common carotid
arteries. PWv was calculated from measurements of pulse
transit time and the distance, according to the following
formula: PWv (m/s) = distance (m)/transit time (s).Measure-
ment of PWv values was con-ducted after abstinence from
caffeine or smoking and after an overnight fast without intake
of antihypertensive drugs. PWv was determined by using
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the SphygmoCor CvMs V9 system and values > 7m/s were
defined as increased.
2.3. Statistical Analysis. Statistical analyses were performed
by using a SPSS software (Statistical Package for the Social
Sciences, version 11.0, SSPS Inc., Chicago, IL, USA). Subjects
were grouped according to the presence of NODAT as
diabetic (𝑛: 57) and nondiabetic (𝑛: 102) patient groups
and according to presence of left ventricular hypertrophy as
increased LVMI (𝑛: 57) and normal LVMI (𝑛: 102) patient
groups. Differences between these groups were analyzed
separately. Patients with NODATwere also divided into three
groups according to their treatment as patients with diet and
life-style changes (𝑛 = 29), oral antidiabetics (𝑛 = 5), and
insulin (𝑛 = 23) for further analysis.
Normality of data was analyzed by using a Kolmogorov-
Smirnov test. All numerical variables with normal distri-
bution were expressed as the means ± standard deviations
(SD), while variables with skew distribution were expressed
asmedians and interquartile range (IR). Categorical variables
were expressed as percentages and compared by chi-square
test. Normally distributed numeric variables were analyzed
by independent samples 𝑡 or one-way ANOVA (post hoc
Tukey) tests according to distribution normality. Skew dis-
tributed numeric variables were compared using the Mann-
Whitney𝑈 and Kruskal-Wallis tests according to distribution
normality. Spearman and Pearson Correlation tests were
used for correlation analyses. Linear regression analysis was
performed to assess the major determinant of high LVMI
between correlated variables. A𝑃 value< 0.05was considered
as statistically significant.
3. Results
3.1. NODAT and Biochemical Parameters. Among 159
patients, 57 (32.2%) patients were with NODAT who were
significantly older than patients without diabetes (43.2 ± 10.7
versus 37.0 ± 10.3 years, 𝑃: 0.0001, Table 1).
There was no significant difference between groups
in means of biochemical parameters except posttransplant
triglyceride levels which were slightly higher in NODAT
group (198.2 ± 93.1 versus 164.3 ± 101.9mg/dL, 𝑃: 0.03,
Table 1). FPG and HbA1c levels were also higher in NODAT
group as expected.
3.2. NODAT and Anthropometric Measurements. Patients
with NODAT also had significantly higher BMI than patients
withoutNODAT (28.5±5.4 versus 24.7±4.1 kg/m2,𝑃: 0.0001).
In body composition analysis, fat mass (20.4 ± 9.0 versus
15.3 ± 8.2 kg, 𝑃: 0.001) and fat free mass (8.5 ± 3.7 versus
5.9±4.2 kg,𝑃: 0.001) were significantly higher in patients with
NODAT (Table 1).
There was no statistically significant difference between
patients with and without NODAT by means of using statins,
ACE inhibitors, or ARB (𝑃 > 0.05) (Table 1). There was no
statistically significant difference in CMV infection history
between patients with and without NODAT (14 (24.5%)
versus 28 (26.7%), resp.) (𝑃: 0.861) (Table 1).
3.3. NODAT andCardiovascular Indices. Weobserved higher
office systolic BP level (134.4±24.5 versus 122.0±45.1mmHg,
𝑃: 0.023) in patients with NODAT. The percentage of
patients with high LVMI (>130 g/m2) was significantly higher
in patients with NODAT (63.2% versus 21.6%, 𝑃: 0.0001,
Table 1). Patients with NODAT had significantly higher PWv
(7.37±1.9 versus 6.68±2.16m/s 𝑃: 0.033) and LVMI (151.9±
47.9 versus 125.9±45.05 g/m2,𝑃: 0.001) compared to patients
without NODAT (Table 1).
3.4. NODAT and LVMI Groups. Further analysis was done
after dividing study population into two groups according
to LVMI as follows: LVMI > 130 g/m2 (𝑛: 57) and LVMI
≤ 130 g/m2 (𝑛: 102, Table 2). We observed higher office
systolic (143.9 ± 17.1mmHg versus 130.7 ± 21.9mmHg,
𝑃: 0.0001) and diastolic (87.9 ± 10.4mmHg versus 82.3 ±
14.7mmHg, 𝑃: 0.01) BP, serum triglyceride (193.9 ± 88.2
versus 164.4 ± 105.3mg/dL, 𝑃: 0.047), glucose (119.1 ± 52.2
versus 93.8 ± 22.0mg/dL, 𝑃: 0.0001), age (𝑃: 0.007), and
HbA1c (7.4 ± 1.6% versus 6.3 ± 1.2%, 𝑃: 0.0001) levels
in patients with LVMI >130 g/m2 (Table 2). Serum creati-
nine levels were significantly higher in patients with LVMI
>130 g/m2 (1.4 ± 0.5 versus 1.2 ± 0.5mg/dL, 𝑃: 0.049). Serum
calcium, phosphorus, parathyroid hormone (PTH), albumin,
hemoglobin, and pretransplantation lipid parameters were
similar in both groups (Table 2). Body composition analysis
and body compartments of both LVMI groups were similar
(Table 2).Thepercentage of patients with PWv> 7m/s tended
to be higher in patients with higher LVMI but this difference
was not statistically significant (34.8% g/m2 versus 30.7 g/m2,
𝑃: 0.340).
3.5. NODAT Treatment Groups. There was no significant
difference in LVMI, PWv, or HbA1c levels between NODAT
treatment groups (𝑃 > 0.05, Table 3). Only LVMI of patients
under insulin therapy was significantly higher than patients
withoutNODAT (158.11±66.41 versus 125.9±45.05,𝑃: 0.05).
When we analyzed relationship between glucose regulation
and LVMI when the patients were grouped according to
HbA1c levels we observed that LVMI was still significantly
higher in NODAT patients with low HbA1c levels (<6.5%
HbA1c levels, 𝑛: 33) than patients without NODAT (147.4 ±
32.31 versus 134.6 ± 50.02 g/m2, 𝑃: 0.013).
Linear regression analysis of factors affecting left ventric-
ular mass revealed that HbA1c was the major determinant of
LVMI (𝑃: 0.026, 𝛽: 0.361) (Figure 1).
4. Discussion
New-onset diabetes after transplantation is a serious
metabolic complication that has been reported to develop
in 2–53% of all solid organ transplants and 4 to 25% of
renal transplant recipients [24–26]. These wide variations
in reported incidences are due to lack of uniform definition
used, presence of variable risk factors in population under
study, method of detection, and duration of follow-up [27].
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Table 1: The clinical and biochemical parameters of patients according to NODAT groups.
Patients with NODAT
(𝑛: 57)
Patients without NODAT
(𝑛: 102) 𝑃 value
Age (years) 43.2 ± 10.7 37.0 ± 10.3 0.0001
Gender (M) 35 (60.3%) 83 (68.0%) 0.198
Dialysis duration (months) 56.5 ± 59.1 32.1 ± 39.0 0.010
Posttransplant duration (months) 50.3 ± 59.9 57.4 ± 54.5 0.393
Pretx T. Chol (mg/dL) 173.8 ± 45.9 171.3 ± 50.9 0.296
Pretx LDL Chol (mg/dL) 92.6 ± 33.8 97.3 ± 34.3 0.506
Pretx HDL Chol (mg/dL) 41.1 ± 14.5 42.7 ± 17.9 0.457
Pretx triglyceride (mg/dL) 185.6 ± 125.14 158.4 ± 86.4 0.139
GFR (mL/min) 68.68 ± 23.08 69.44 ± 24.9 0.841
Creatinine (mg/dL) 1.2 ± 0.5 1.3 ± 0.5 0.472
Albumin (g/L) 4.0 ± 0.4 4.1 ± 0.3 0.169
Hemoglobin (g/dL) 13.2 ± 1.9 13.2 ± 1.9 0.832
T. Chol (mg/dL) 215.9 ± 66.3 209.0 ± 46.4 0.483
LDL Chol (mg/dL) 116.4 ± 40.7 119.7 ± 34.3 0.599
HDL Chol (mg/dL) 47.7 ± 15.6 49.0 ± 13.4 0.605
Triglyceride (mg/dL) 198.2 ± 93.1 164.3 ± 101.9 0.030
Calcium (mg/dL) 9.4 ± 0.5 9.2 ± 0.6 0.475
Phosphorus (mg/dL) 3.1 ± 0.7 3.2 ± 0.7 0.248
PTH (pcg/mL) 193.4 ± 24.4 148.8 ± 96.9 0.092
Glucose (mg/dL) 136.2 ± 52.2 87.3 ± 9.2 0.0001
Office SBP (mmHg) 134.4 ± 24.5 122.0 ± 45.1 0.023
Office DBP (mmHg) 83.3 ± 16.0 76.9 ± 28.5 0.065
HbA1c 7.39 ± 1.33 5.27 ± 1.131 0.0001
BMI (kg/m2) 28.5 ± 5.4 24.7 ± 4.1 0.0001
Fat mass (kg) 20.4 ± 9.0 15.3 ± 8.2 0.001
Fat free mass (kg) 55.5 ± 12.4 54.7 ± 9.6 0.707
Visceral fat mass (kg) 8.5 ± 3.7 5.9 ± 4.2 0.001
Muscle mass (kg) 53.6 ± 9.7 52.0 ± 9.2 0.341
PWv (m/s) 7.37 ± 1.9 6.68 ± 2.16 0.033
PWv >7 m/s 37 (63.8%) 29 (23.8%) 0.0001
LVMI (g/m2) 151.9 ± 47.9 125.9 ± 45.05 0.001
LVMI >130 g/m2 37 (63.8%) 29 (23.8%) 0.001
ACEI 7 (13.5%) 21 (17.5%) 0.339
AT II 12 (23.1%) 31 (25.8%) 0.429
Statin 12 (23.1%) 26 (21.7%) 0.492
Tacrolimus 28 (54.9%) 44 (41.9%) 0.306
Cyclosporin-A 13 (25.5%) 33 (31.4%) 0.149
Sirolimus 10 (19.6%) 28 (26.7%) 0.306
CMV infection 14 (24.5%) 28 (26.7%) 0.861
The incidence of NODAT in our study group was 23.59%
consistent with previous literature.
Posttransplant hyperglycemia usually develops in pa-
tients with a high cardiovascular risk profile; older recipients
with higher BMI; or those with insulin resistance before
transplantation [28]. Older age of recipients is considered as
the most important risk factor for NODAT [8]. Consistent
with this data, our patients with NODAT were significantly
older and had higher BMI, fat mass, and fat free mass
compared to patients without NODAT. Chakkera et al.
observed that pretransplant elevated serum triglyceride level
was an important risk factor for NODAT development [29].
Hypertriglyceridemia is known to be associated with insulin
resistance and atherosclerosis in previous studies [30]. In
our study, patients with NODAT had nonsignificantly higher
pretransplant serum triglyceride levels than patients without
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Table 2: The clinical and biochemical parameters of patients according to LVMI groups.
LVMI > 130 g/m2
(𝑛: 57)
LVMI ≤ 130 g/m2
(𝑛: 102) 𝑃 value
Age (years) 42.2 ± 10.6 37.2 ± 10.5 0.002
Gender (M) 44 (66.7%) 74 (64.9%) 0.871
Dialysis duration (months) 47.0 ± 49.5 35.8 ± 46.3 0.165
Posttransplant duration (months) 54.6 ± 52.2 55.4 ± 53.7 0.930
GFR (mL/min) 63.23 ± 23.87 72.65 ± 24.01 0.012
Creatinine (mg/dL) 1.4 ± 0.5 1.2 ± 0.5 0.049
Albumin (g/L) 4.0 ± 0.4 4.1 ± 0.3 0.43
Hemoglobin (g/dL) 13.2 ± 2.0 13.2 ± 1.9 0.845
T. Chol (mg/dL) 213.9 ± 52.4 209.7 ± 54.1 0.610
LDL Chol (mg/dL) 120.0 ± 40.0 117.9 ± 34.3 0.723
HDL Chol (mg/dL) 47.6 ± 14.2 49.2 ± 14.0 0.462
Triglyceride (mg/dL) 193.9 ± 88.2 164.4 ± 105.3 0.047
Calcium (mg/dL) 9.4 ± 0.6 9.2 ± 0.6 0.065
Phosphorus (mg/dL) 3.1 ± 0.5 3.2 ± 0.7 0.301
PTH (pcg/mL) 170.8 ± 115.1 157.2 ± 131.5 0.492
Glucose (mg/dL) 119.1 ± 52.2 93.8 ± 22.0 0.0001
Office SBP (mmHg) 143.9 ± 17.1 130.7 ± 21.9 0.0001
Office DBP (mmHg) 87.9 ± 10.4 82.3 ± 14.7 0.01
HbA1c 7.4 ± 1.6 6.3 ± 1.2 0.0001
BMI (kg/m2) 26.9 ± 4.4 25.3 ± 4.9 0.102
Fat mass (kg) 17.7 ± 8.1 16.2 ± 9.0 0.310
Fat free mass (kg) 55.8 ± 12.3 54.5 ± 9.4 0.532
Visceral fat mass (kg) 7.25 ± 3.8 6.42 ± 4.43 0.237
Muscle mass (kg) 53.7 ± 9.9 51.8 ± 9.0 0.244
Table 3: HbA1c, PWv, and LVMI values of patients according to NODAT treatment modalities.
Patients without NODAT
(𝑛 = 102)
Diet and life-style changes
(𝑛 = 29)
Oral antidiabetics
(𝑛 = 5)
Insulin
(𝑛 = 23) 𝑃 value
HbA1c (%) 5.27 ± 1.131 7.52 ± 0.77 7.20 ± 0.14 8.03 ± 1.46 0.273
PWv (m/s) 6.68 ± 2.16 9.25 ± 1.54 8.58 ± 0.78 9.19 ± 1.54 0.557
LVMI (g/m2) 125.9 ± 45.05∗ 143.80 ± 31.84 170.54 ± 18.46 158.11 ± 66.41∗ 0.05∗
∗
𝑃 value for LVMI between patients without NODAT and patients with NODAT under insulin therapy.
diabetes. In our subjects, longer dialysis before transplanta-
tion also appeared to confer a higher risk of diabetes after
kidney transplantation.
The association between the use of tacrolimus and the
development of NODAT has been clearly established previ-
ously [1, 31]. However in our study population there was no
significant difference between immune suppressive regimes
in terms of the frequency of NODAT. This may be because
of the relatively small number of patients included that did
not reveal a statistical significance, though there was a higher
tendency in the tacrolimus group to develop NODAT.
Although steroids are known to have a strong diabeto-
genic effect [32, 33], we did not observe any association with
NODAT. This finding could be explained by an intentional
decrease in the dose of corticosteroids when diabetes is
recognized as in our transplantation outpatient clinic and
the low maintenance dose of steroids used by the patients.
This clinical practice was observed in a previous study with
steroid dose decline [34]. As we excluded patients with
acute rejection episodes, our patients had not received any
pulse steroid regimen. There is also some evidence about the
influence of nonimmunosuppressive drugs such as statins
and antihypertensives on development of NODAT [35, 36].
In contrast to these studies, we did not find any relationship
between NODAT and the use of statins, ACE inhibitors, or
ARB in our study group.
Left ventricular hypertrophy, one of the structural alter-
ations involved in diabetic cardiomyopathy [37–39], has
also been associated with abnormal glucose tolerance in
several epidemiological investigations [40–42]. We observed
that the LVMI was significantly higher among patients who
developed NODAT. The influence of glucose intolerance,
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Figure 1: Linear regression analysis of factors affecting left ventric-
ular mass revealed that HbA1c was the major determinant of LVMI
(𝑃: 0.026, 𝛽: 0.361).
insulin resistance, and metabolic syndrome on the LVMI has
been reported by some previous remarkable epidemiologic
studies [43, 44], in hypertensive nondiabetic [45, 46] and
diabetic nontransplanted subjects [47, 48]. In this study,when
we compared patients according to their LVMI, we observed
higher office systolic and diastolic blood pressure, serum
triglyceride, creatinine, glucose, and HbA1c levels in patients
with LVMI >130 g/m2. Patients with a high LVMI showed
worse renal function, associated with greater proportion of
subjects with diabetes mellitus after transplantation. Left
ventricular hypertrophy has been strongly linked to renal
functional impairment [11, 12, 49, 50]. In this study, higher
LVMI was associated with worse renal function, having
significantly higher creatinine levels and lower GFR than
patients with LVMI ≤130 g/m2. In the context of both left
ventricular hypertrophy and NODAT, markers of increased
oxidative stress are known to be elevated, leading to graft
failure [51].
In diabetes, nonenzymatic glycation of proteins and for-
mation of advanced glycation endproducts have the potential
to quench nitric oxide and then diminish the vasodilatory
capacity of the peripheral muscular arteries [52, 53]. Reduced
nitric oxide availability may cause vasoconstriction and alter
growth of vascular muscle, as well as producing cellular
injury in prolonged hyperglycemia [54]. The formation of
advanced glycation endproducts on collagen is enhanced
within the arterial wall and may also contribute to vascular
injury [55]. Thus prolonged hyperglycemia can modify the
timing andmagnitude of the pulsewave reflection to augment
systolic load of the left ventricle [54]. The impaired systolic
loading condition of the left ventricle may cause the heart to
adapt to muscular hypertrophy and may increase the ratio
of left ventricular weight to body weight, an indicator of
cardiac hypertrophy [54]. Accordingly, regression analysis
of risk factors for the development of LVMI revealed that
HbA1c was the major determinant of LVMI, indicating the
importance of serum glucose control. All of these findings
suggest that glucose homeostasis plays pivotal roles in the
evolution of ventricular mass after renal transplantation. In
the diabetic population,HbA1c level is a validated and reliable
marker for glycemic control and for predicting morbidity
and mortality [56]. But even in NODAT patients with good
glycemic control and low HbA1c levels (<6.5% HbA1c levels)
LVMI was still significantly greater to those without NODAT.
Our result showed that though well controlled the presence
of NODAT should be accepted not only as a primary risk
factor but also as a direct prometer of the development of left
ventricular hypertrophy in renal transplant recipients.
High pulse wave velocity is a universal marker of aortic
stiffness and the link between pulse pressure and NODAT
is unknown [7]. Aortic stiffness leading to microvascular
injury within the pancreas circulation (leading to impaired
insulin secretion) may be one of the mechanisms of NODAT
[57]. Interestingly, hypertension was found to be a risk factor
for the development of diabetes mellitus in the general
population [58]. This association suggests a link between
vascular damage and the onset of diabetes [59]. Ultrastruc-
tural alterations of vascular pancreatic islets with loss of
endothelial cell homeostasis have been suggested to play a
key role in the pathogenesis of beta-cell dysfunction [60].
Our data showed that NODAT is related with increased
PWv. Hyperglycemia and associated relative deficiency of
insulin secretion may negatively modulate a wide array of
cardiovascular risk factors, including redox imbalance and
increased oxidative stress [61]. In NODAT, the formation of
advanced glycation endproducts is also enhanced within the
arterial wall andmay contribute to vascular injury [55]. New-
onset diabetes after transplantation and arterial stiffness have
a bimodal relationship in a cause and effect manner. Presence
of NODAT, hypertension, older age, and longer pretransplant
dialysis duration were all related with increased PWv as in
previous literature [7, 8, 28, 62]. All these comorbidities
aggregate endothelial dysfunction and enhance atherosclero-
sis and therefore increase arterial stiffness.
Our study has several limitations. It is a cross sectional
study, and our findings need to be confirmed in large
long-term prospective studies. Pretransplantation echocar-
diographic and arterial pulse wave evaluations of patients
were absent, so we were not able to discuss the initiation or
the progression of LVMI or arterial stiffness. Pretransplant
OGTT was not routinely assessed at our center. There are
other less consistent risk factors linked to development of
NODAT, like HLA phenotype, genetic polymorphisms of
interleukins, and donor characteristics, through levels of
CNIs. These issues were not addressed in our study. Patients’
antihypertensive medication was recorded according to the
type of the class and we could not assess the influence of the
type and dose because of the small number of patients.
The current study confirmed the association of traditional
risk factors including age, presence of obesity, and long
dialysis duration with the development of NODAT. Patients
with NODAT should be accepted as a high risk population
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with higher prevalence of left ventricular hypertrophy and
vascular stiffness. Prevention of NODAT related cardiovas-
cular morbidity may be accomplished with early detection
of this metabolic disorder with corresponding therapeutic
interventions such as change in lifestyle, weight loss, selection
of an appropriate immunosuppressive regimen, and use of
antidiabetic drugs. Thus, regular screening of NODAT and
initiation of proper treatment and better metabolic control
at earliest possible should be the integral part of overall
renal transplant management. Relevance and therapeutic
consequences must be determined in large-scale prospective
studies.
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